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Paediatric HIV disclosure in South Africa – caregivers’ 
perspectives on discussing HIV with infected children
Keymanthri Moodley, Landon Myer, Desiree Michaels, Mark Cotton
To the Editor: Most paediatric HIV infections in South Africa 
are transmitted perinatally. Lack of widely available HIV 
treatment means that most children do not survive to an age at 
which disclosure becomes a relevant concern. However, with 
the expansion of HIV treatment programmes the proportion of 
HIV-infected children surviving to an advanced age is likely 
to increase substantially during the next 5 - 10 years. A similar 
phenomenon was observed in Europe and North America with 
the advent of antiretroviral therapy (ART) in the mid-1990s, 
and in resource-rich settings approximately half of perinatally 
infected children are expected to survive beyond 13 years of 
age.1 
   While guidelines on the discussion and disclosure of HIV 
infection among adult patients have received considerable 
attention, there are no such guidelines focusing on the 
disclosure of paediatric HIV infection in South Africa and other 
resource-limited settings. Yet in many respects disclosure and 
discussion of paediatric HIV infection may be more complex 
than with adult infection. Research from the USA and Europe 
has shown that when and how a parent discloses to a child can 
affect the provision of care for the child2 and may influence the 
child’s psychosocial adjustment and development.3 Beyond 
the parent-child relationship, public disclosure of a child’s HIV 
status can have significant impact on children and families.4,5 
Particular sensitivity is required in the case of larger families 
or households that include both HIV-infected and uninfected 
members.6 As HIV infection remains highly stigmatised in 
many communities, disclosure of paediatric HIV infection may 
also be accompanied by threats to the child’s physical and/or 
psychological health.7 
   To date there has been no empirical research investigating 
issues of paediatric HIV disclosure in sub-Saharan Africa, 
although studies from other regions have suggested that 
caregivers may seek to balance the perceived risks and benefits 
of disclosure. Most commonly, this manifests in caregivers’ 
attempts to avoid deceiving the infected child out of respect 
for the child’s emerging autonomy, while seeking to protect 
the child (and often the caregiver) from perceived emotional 
confusion and/or social stigma.8,9 
   Given the complex issues involved in paediatric HIV 
disclosure, and the lack of insight into these issues in resource-
limited settings, there is a clear need for research examining 
paediatric HIV disclosure in South Africa. We investigated the 
concerns raised by parents and caregivers when considering 
discussing HIV with infected children.
Methods
The study was conducted at a paediatric HIV clinic in a large 
urban hospital in Cape Town. The clinic receives children 
referred from primary care services around the city and 
patients from paediatric wards at the hospital. All interviews 
took place in a separate, private office at the clinic between 
April and June 2004.
   A total of 174 semi-structured interviews were conducted 
with consecutive caregivers waiting at the clinic, representing 
a total sample of caregivers of children attending this service. 
The questionnaire was developed with inputs from health 
care providers working with HIV-infected children and 
was pilot-tested and revised. In addition to fully structured 
items, the final instrument contained a number of open-
ended questions investigating participants’ experiences or 
preferences. Interviews lasted approximately 25 minutes and 
were conducted by an experienced interviewer working in the 
caregiver’s home language (isiXhosa, English or Afrikaans). 
   Data were analysed using SAS Version 9.1 (SAS Corporation, 
Cary, USA). Descriptive analyses employed means, medians 
and proportions, which were compared using Student’s t-tests, 
Wilcoxon’s rank-sum tests, and chi-square tests, respectively. 
Logistical regression models were used to examine the 
relationship between caregiver or child characteristics and 
disclosure-related outcomes after adjusting for participant 
demographics. All statistical tests are two-sided at α = 0.05. 
   All participants provided written informed consent before 
data collection, and ethical approval to conduct the study was 
granted by the Research Ethics Committee of Stellenbosch 
University.
Results 
The mean age of caregivers interviewed was 33 years (range 
17 - 73 years). The majority (91%, N = 158) were female. Most 
caregivers were either a parent of the infected child (80%, 
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N = 139) or a grandparent (10%, N = 17), and most of those 
interviewed (95%) described themselves as primary caregivers 
of the child (N = 165).  The 174 caregivers were accompanying 
176 children who were patients at the paediatric HIV clinic. 
The median age of child patients was 3.3 years (range 5 months 
- 11 years) and most of the children (74%, N = 131) were 
younger than 6 years of age.
   Of the caregivers interviewed, only 9% (N = 16) had 
discussed HIV with the infected child. The mean age of 
children who had been told their HIV status was 8.1 years 
(range 5 - 11 years). Among the 127 HIV-infected caregivers 
(representing 73% of the sample), those who had discussed 
their own infection with the child were more than 7 times more 
likely to have disclosed the child’s status to him/her (p = 0.07 
after adjusting for age of the child).
   Caregivers gave a median age of 11 years as the best time 
to have a general discussion regarding the child’s illness, 
and 12 years as the best age to tell a child about his/her HIV 
infection specifically. Of the caregivers interviewed 83% felt 
that the parent or primary caregiver would be the best person 
to discuss the diagnosis with the child, while 16% felt it would 
be best for a health care provider (doctor, nurse or counsellor) 
to tell the child. 
   When asked for reasons for disclosure, 98% of caregivers 
(162/165) said they felt that the child has a right to know his/
her HIV status, while 90% (151/167) gave reasons related to 
the child’s mental health. In addition, 70% of caregivers (N = 
122) said that the availability of ART could make it necessary 
to discuss the child’s HIV status with him/her. In discussing 
barriers to disclosure, most caregivers (73%) said that they 
were afraid of the child discussing his/her HIV infection with 
other people. In particular, most caregivers were concerned 
about the child discussing his/her infection with friends or 
children at school (89%, N = 154) and/or neighbours or in the 
community (59%, N = 102).
   Most caregivers said that doctors should also be involved in 
disclosing HIV infection to a child. 
   One-quarter of the sample (44 caregivers) reported that 
they had discussed disclosure of the child’s HIV status with a 
health care provider. After adjusting for the child’s age, having 
discussed disclosure with a health care provider was associated 
with disclosure to the child (p = 0.07). Of those who had not 
discussed disclosure with a health care provider, 96% stated 
that they would like to do so. 
Discussion
With most caregivers recognising both the importance of 
paediatric HIV disclosure and the challenges surrounding 
this process, these findings emphasise the complexity of 
discussing HIV status with infected children. In this study the 
low overall proportion of children who had been told their 
HIV status is related to the relatively young age distribution of 
patients attending the paediatric clinic.  However, only 26% of 
children older than 6 years attending the clinic knew their HIV 
diagnosis, suggesting that there may be substantial barriers to 
discussing HIV status with children in this setting. 
   These findings are in keeping with those of previous 
studies where the child’s age was found to be an important 
predictor of whether or not disclosure had occurred.10,11 Even 
though disclosure rates appear somewhat low, there is a clear 
difference between the age at which disclosure actually occurs 
(on average 8.1 years of age in this study) and the age at which 
caregivers would prefer disclosure to occur (approximately 12 
years of age in this study). This discrepancy requires further 
research attention, and if documented more generally, may 
warrant attention from health care providers working with 
infected children and their families.
   Most caregivers in this study were parents who believed 
it was their responsibility to disclose the diagnosis to the 
child. Similarly, a Thai study found that 73% of caregivers 
believed that as parents they should disclose diagnosis to the 
child.12  According to these data, caregivers saw themselves as 
primarily responsible for these discussions but most wanted 
a doctor to support them in the disclosure process. However, 
only 25% of the caregivers had actually discussed disclosure 
issues with a health care provider, and the majority who had 
not indicated that they would like to have this discussion. 
This suggests that paediatric HIV disclosure requires greater 
attention as part of clinical consultations in this setting. 
   The generalisability of these findings is limited by the 
young mean age of patients attending the clinic, and it will be 
important to monitor patterns of disclosure as an increasing 
number of infected children in South Africa survive for longer 
periods on ART. Furthermore, these findings may reflect norms 
and opinions among caregivers at a single urban clinic, but 
these issues also require examination in other parts of the 
country. Future research should also include both qualitative 
and quantitative methods to assess the effects of different 
disclosure styles on children of different ages and backgrounds.
   In summary, this study highlights the growing importance 
of paediatric HIV disclosure, particularly in the context of the 
scale-up of HIV treatment services in many parts of South 
Africa. Greater attention to issues of disclosure of HIV status 
to infected children may contribute to the improved quality of 
long-term care for this vulnerable population. 
    This research was funded through a grant from the South 
African Medical Research Council. 
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HIV seroconversion during pregnancy in the Tygerberg 
region of Cape Town
G B Theron, J Schoeman, E Carolus
To the Editor: AIDS is one of the leading causes of death 
in children, with mother-to-child-transmission being the 
dominant mode of HIV acquisition among young children. A 
high viral load is associated with a higher risk of transmission.1 
Seroconversion during pregnancy results in viraemia and high 
viral load.  
    The current Perinatal Maternal to Child Transmission 
(PMTCT) programme in the Western Cape provides voluntary 
counselling and testing at the booking visit.  Women who 
become HIV-positive during pregnancy do not receive 
prophylaxis during labour, as they are believed to be HIV-
negative. Especially at risk are women who book early, 
increasing the interval between testing and delivery. These 
women will also not receive counselling on the best method 
of infant feeding, increasing the HIV risk. Repeat HIV testing 
during late pregnancy will identify these cases.  However, 
before extending additional resources to retest during 
pregnancy the extent of the problem needs to be verified.2
   Consecutive HIV-negative women tested before 24 weeks’ 
gestation at antenatal clinics in the Tygerberg region were 
approached to take part in the study between 36 and 38 weeks 
of pregnancy. Patients who accepted repeat testing received 
pre-test counselling and gave signed informed consent 
followed by HIV rapid testing and post-test counselling. Five 
hundred patients were recruited, with the sample size at 
each site proportionate to the clinic size. The OraQuick Rapid 
Test (OraShure Technologies, Bethlehem, Penn., USA) was 
used for screening and the Pareekshak HIV Tri-Line (BHAT 
Bio-Tech, Bangalore, India) for confirmation. In the event of 
discordance an enzyme-linked immunosorbent assay (ELISA) 
was performed.
   A total of 532 patients were recruited from February to 
September 2004; 524 (98.5%) consented to a second test (Table 
I). The mean age of the study patients at the sites ranged from 
22.9 to 29.3 years, the median gravidity from 1 to 2 and the 
proportion of primigravidas from 14.4% to 62.4%.  The mean 
gestational age at the first antenatal visit ranged from 15.9 
to 18.4 weeks and at retesting from 36.7 to 38.1 weeks.  The 
percentage of patients who declined screening at the first visit 
ranged from 4.9% to 20.3%, and the HIV seropositive rate 
ranged from 0.9% to 16.7% (Table I) according to PMTCT data 
collected from January to June 2004. No patient seroconverted 
during pregnancy. One discordant rapid test occurred, but the 
ELISA test was negative.
   The seroconversion rate in the Tygerberg region appears to 
be lower than the 5% reported at Chris Hani Baragwanath 
Hospital (Rwakvendela et al., unpublished data, 2002) and the 
2.2% reported at King Edward VIII Hospital3 following the 
retesting of 390 and 191 patients, respectively.  Retesting during 
late pregnancy could be restricted to women with high-risk 
behaviour.
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Table I. Characteristics of clinics included in the study
  HIV pre-  Declined test 
Clinic N valence (%) at booking (%)
Tygerberg Hospital   53   8.7    4.9
Belhar   47   0.9  13.8
Delft 142 16.7  12.8
Bishop Lavis   68 0.01  20.3
Elsiesrivier 148   1.7  12.6
Bellville-Suid   42   9.4    8.9
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